Cargando…
Analytical Validation of NavDx, a cfDNA-Based Fragmentomic Profiling Assay for HPV-Driven Cancers
The NavDx(®) blood test analyzes tumor tissue modified viral (TTMV)-HPV DNA to provide a reliable means of detecting and monitoring HPV-driven cancers. The test has been clinically validated in a large number of independent studies and has been integrated into clinical practice by over 1000 healthca...
Autores principales: | Gunning, Alicia, Kumar, Sunil, Williams, Cassin Kimmel, Berger, Barry M., Naber, Stephen P., Gupta, Piyush B., Del Vecchio Fitz, Catherine, Kuperwasser, Charlotte |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9955790/ https://www.ncbi.nlm.nih.gov/pubmed/36832208 http://dx.doi.org/10.3390/diagnostics13040725 |
Ejemplares similares
-
Integrated fragmentomic profile and 5-Hydroxymethylcytosine of capture-based low-pass sequencing data enables pan-cancer detection via cfDNA
por: Zhang, Zhidong, et al.
Publicado: (2023) -
Microfluidic Technologies for cfDNA Isolation and Analysis
por: Xu, Zheyun, et al.
Publicado: (2019) -
Evaluation of the Analytical Performance of Oncomine Lung cfDNA Assay for Detection of Plasma EGFR Mutations
por: Cho, Yong Gon, et al.
Publicado: (2023) -
Combinatorial Power of cfDNA, CTCs and EVs in Oncology
por: Keup, Corinna, et al.
Publicado: (2022) -
cfDNA Sequencing: Technological Approaches and Bioinformatic Issues
por: Bohers, Elodie, et al.
Publicado: (2021)